Product Information
LITHOBID ER 300 MG TABLET is a brand product labeled by ANI Pharmaceuticals, Inc., priced at $12.0194 per EA under NDC 62559028001. Its NADAC has been published 259 times since Jul 23, 2014.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lithium carbonate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559028001
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LITHIUM CARBONATEApproval Type
New Drug (NDA)
FDA Application
NDA018027FDA Approved
Before 1982
TE Code
AB
On Market Since
7/1/2014
Pharmacological Classes
Price Statistics
The NADAC for LITHOBID ER 300 MG TABLET has been published 259 times since Jul 23, 2014, and over the history we have for it it has risen 314.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.0194 per EA |
|---|---|
| All-time high | $12.2055 (Jun 12, 2024) |
| All-time low | $2.9000 (Jul 23, 2014) |
| 52-week high | $12.1317 |
| 52-week low | $11.8265 |
| Median price | $7.0685 |
| Average price | $8.8035 |
| Largest weekly change | +67.6% (Apr 17, 2024) |
| Weeks tracked | 259 |
| Tracking since | Jul 23, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lithium carbonate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lithium carbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LITHOBID ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LITHOBID ER 300 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $12.0194 per EA (NDC 62559028001), effective Sep 30, 2026.
How has the price of LITHOBID ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LITHOBID ER 300 MG TABLET has risen 314.5%. It has been tracked across 259 weekly CMS publications since Jul 23, 2014.
What are the highest and lowest recorded NADAC prices for LITHOBID ER 300 MG TABLET?
Since Jul 23, 2014, the NADAC for LITHOBID ER 300 MG TABLET has ranged from a low of $2.9000 (Jul 23, 2014) to a high of $12.2055 (Jun 12, 2024), with a median of $7.0685 per EA.
Are there cheaper alternatives to LITHOBID ER 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LITHOBID ER 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LITHOBID ER 300 MG TABLET?
LITHOBID ER 300 MG TABLET (NDC 62559028001) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a brand product.